文献速递急性肾损伤

溶血相关血红蛋白管型肾病源于多种临床病理疾病

Hemolysis-associated hemoglobin cast nephropathy results from a range of clinicopathologic disorders.
PubMed 文献 · Kidney Int · 2019-09-16

该回顾性分析纳入27例溶血相关血红蛋白管型肾病患者,平均年龄47岁,女男比1.3:1,均表现为急性肾损伤(平均血肌酐8.0 mg/dL)。病因包括自身免疫性溶血性贫血(30%)、药物(26%)等。平均随访9个月后平均血肌酐降至1.3 mg/dL,78%患者肾功能恢复正常。

要点

  • 溶血相关血红蛋白管型肾病是急性肾损伤的重要病因,需早期识别。
  • 病因多样,自身免疫性溶血性贫血和药物最常见。
  • 治疗关键在于消除血管内溶血的致病驱动因素,多数肾功能可恢复。

核心结论

  • 溶血相关血红蛋白管型肾病是临床和病理医生应识别的重要疾病实体,治疗取决于消除血管内溶血的致病驱动因素。

研究设计与样本

  • 回顾性分析27例溶血相关血红蛋白管型肾病患者,平均年龄47岁(范围19-79),女男比1.3:1。

主要发现

  • 所有患者均表现为急性肾损伤,平均血肌酐8.0 mg/dL(范围2.9-17.0)。
  • 病因包括自身免疫性溶血性贫血(30%)、药物(26%)、阵发性睡眠性血红蛋白尿(7%)、操作/机械原因(7%)、输注不相容血液(4%)、毒素摄入(4%)、弥散性血管内凝血(4%)和血红蛋白病(4%)。
  • 所有活检均显示急性肾小管损伤和色素性蛋白管型,血红蛋白免疫组化阳性。
  • 平均随访9个月(范围0.5-26),平均血肌酐1.3 mg/dL(范围0.6-3.3),78%患者肾功能恢复正常。

临床怎么用

  • 对急性肾损伤伴血管内溶血证据的患者,应怀疑溶血相关血红蛋白管型肾病并及时肾活检。
  • 治疗重点在于识别并消除溶血的病因(如停用可疑药物、治疗自身免疫性溶血性贫血等)。

局限性

  • 回顾性研究,样本量较小(27例),可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Intravascular hemolysis is relatively rare but can lead to acute kidney injury (AKI), from increased destruction of erythrocytes and release of free hemoglobin. Since hemolysis and hemoglobinuria are known causes of acute kidney injury we sought to define clinicopathologic findings and outcomes of patients with hemolysis-associated hemoglobin cast nephropathy through a retrospective analysis of 27 cases. The mean patient age was 47 years (range 19-79) and the female-to-male ratio was 1.3:1. All patients presented with AKI with a mean serum creatinine of 8.0 (range 2.9-17.0) mg/dL. Etiologies included autoimmune hemolytic anemia (30%), medication (26%), paroxysmal nocturnal hemoglobinuria (7%), procedural/mechanical causes (7%), transfusion of incompatible blood (4%), toxin ingestion (4%), disseminated intravascular coagulation (4%), and hemoglobinopathy (4%). All biopsies showed acute tubular injury and pigmented, proteinaceous casts characterized by positive hemoglobin immunohistochemistry. After a mean follow-up of nine months (range 0.5-26), the mean serum creatinine was 1.3 (range 0.6-3.3) mg/dL, with 78% of patients returning to normal kidney function. Thus, based on our clinicopathologic case series, hemolysis-associated hemoglobin cast nephropathy is an important entity for clinicians and pathologists to recognize as treatment hinges upon elimination of the pathogenic driver of intravascular hemolysis.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Dvanajscak Z, Walker PD, Cossey LN, et al. Hemolysis-associated hemoglobin cast nephropathy results from a range of clinicopathologic disorders. Kidney Int. 2019. PMID: 31668630. doi:10.1016/j.kint.2019.08.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。